The flu treatment Relenza looks unlikely to be made available on the National
Health Service in Britain. As New ÒÁÈ˾þà went to press, the National
Institute for Clinical Excellence was thought to have advised against releasing
the drug, which limits symptoms and hastens recovery. Richard Sykes, chairman of
Glaxo Wellcome, the drug’s maker, is incensed. Yet a company data sheet prepared
in August states that the drug has yet to be shown to work in chronically ill or
immunocompromised patients, who are most at risk from complications of the
flu.
More from New ÒÁÈ˾þÃ
Explore the latest news, articles and features
Popular articles
Trending New ÒÁÈ˾þà articles
1
Mathematicians stunned by AI's biggest breakthrough in mathematics yet
2
The Selfish Gene at 50: Why Dawkins’s evolution classic still holds up
3
Photos reveal unexpected details from the world's first atomic test
4
The ‘doomsday’ glacier’s giant ice shelf is about to break away
5
How I used psychology to come back from the worst year of my life
6
The distant world that is our best hope of finding alien life
7
Epic dreaming is leaving people exhausted and distressed
8
We may finally know why dinosaurs like T. rex evolved tiny arms
9
Putting CO2 into rocks and getting hydrogen out is climate double win
10
The 3 things you need to know about protein, according to an expert
